clinical trial · NCT06814132
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
Merck Sharp & Dohme LLC·phase1·completed·n = 24
Kidney Failure, ChronicEnd-Stage Kidney DiseaseRenal Failure, ChronicRenal Failure, End-StageHealthy ParticipantsMK-5684PrednisoneFludrocortisone acetate
brief summary
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.
started
Apr 7, 2025
primary completion
Oct 4, 2025
completion
Oct 14, 2025
last updated
Oct 23, 2025
official title
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Severe Renal Impairment and With End-stage Renal Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol